European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Publication

European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Journal Paper/Review - Aug 8, 2017

Krieg T, Quaglino P, Petit A, Parodi A, Panelius J, Orteu C, Olszewska M, Krasowska D, Kofoed K, Kárpáti S, Ranki A, Sanchez Schmidt J M, Wutte N J, Worm M, Wolf P, Tanew A, Taieb A, Sunderkötter C, Sticherling M, Skrok A, Seneschal J, Kähäri V, Just U, Rudnicka L, Denton C P, Rongioletti F, Cutolo M, Mouthon L, Cozzio Antonio, Kreuter A, Hunzelmann N, Moinzadeh P, Frasin L A, Smith V, Jalili A, Frances C, Foeldvari I, Braae Olesen A, Bouaziz J, Bali G, Bagot M, Aberer E, Gabrielli A, Knobler R

Citation

Krieg T, Quaglino P, Petit A, Parodi A, Panelius J, Orteu C, Olszewska M, Krasowska D, Kofoed K, Kárpáti S, Ranki A, Sanchez Schmidt J, Wutte N, Worm M, Wolf P, Tanew A, Taieb A, Sunderkötter C, Sticherling M, Skrok A, Seneschal J, Kähäri V, Just U, Rudnicka L, Denton C, Rongioletti F, Cutolo M, Mouthon L, Cozzio A, Kreuter A, Hunzelmann N, Moinzadeh P, Frasin L, Smith V, Jalili A, Frances C, Foeldvari I, Braae Olesen A, Bouaziz J, Bali G, Bagot M, Aberer E, Gabrielli A, Knobler R. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol 2017; 31:1581-1594.

Type

Journal Paper/Review (English)

Journal

J Eur Acad Dermatol Venereol 2017; 31

Publication Date

Aug 8, 2017

Issn Electronic

1468-3083

Pages

1581-1594

Brief description/objective

The term 'sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).